# OnCo record nct05281471 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05281471/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05281471", "NCT05281471" ;
  schema:name "Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)"@en ;
  schema:description "A phase 3 trial testing Olvimulogene nanivacirepvec in ovarian cancer, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05281471/> ;
  schema:dateModified "2026-09-11"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05281471> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2022-08-31" ;
  onco:cancers <https://onco.cc/cancers/ovarian/>, <https://onco.cc/cancers/platinum-resistant-ovarian-cancer/> ;
  onco:drugs <https://onco.cc/drugs/olvimulogene-nanivacirepvec/> ;
  onco:companies <https://onco.cc/companies/genelux/> .